Literature DB >> 20308391

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Douglas J Biedenbach, James E Ross, Shannon D Putnam, Ronald N Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308391      PMCID： PMC2863674          DOI： 10.1128/AAC.00090-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  12 in total

1.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.

Authors:  Maxime Gualtieri; Philippe Villain-Guillot; Jaqueline Latouche; Jean-Paul Leonetti; Lionel Bastide
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

5.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

6.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

7.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease.

Authors:  Ajay K Sethi; Wafa N Al-Nassir; Michelle M Nerandzic; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

10.  A case-control study of community-associated Clostridium difficile infection.

Authors:  M H Wilcox; L Mooney; R Bendall; C D Settle; W N Fawley
Journal:  J Antimicrob Chemother       Date:  2008-04-22       Impact factor: 5.790
View more
  8 in total

1.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Narrow-Spectrum Antibacterial Agents.

Authors:  Roberta J Melander; Daniel V Zurawski; Christian Melander
Journal:  Medchemcomm       Date:  2017-11-06       Impact factor: 3.597

Review 3.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

4.  Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea.

Authors:  Yoav Golan; Lauren Epstein
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

5.  Antibiotic Treatments for Clostridium difficile Infection Are Associated with Distinct Bacterial and Fungal Community Structures.

Authors:  Regina Lamendella; Justin R Wright; Jada Hackman; Christopher McLimans; David R Toole; William Bernard Rubio; Rebecca Drucker; Hoi Tong Wong; Kate Sabey; John P Hegarty; David B Stewart
Journal:  mSphere       Date:  2018-01-10       Impact factor: 4.389

6.  Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.

Authors:  Andrea Dorst; Regina Berg; Christoph G W Gertzen; Daniel Schäfle; Katja Zerbe; Myriam Gwerder; Simon D Schnell; Peter Sander; Holger Gohlke; Karl Gademann
Journal:  ACS Med Chem Lett       Date:  2020-10-14       Impact factor: 4.345

7.  Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.

Authors:  Fredy Chaparro-Rojas; Kathleen M Mullane
Journal:  Infect Drug Resist       Date:  2013-06-28       Impact factor: 4.003

Review 8.  Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.